TWLO Q3 FY12/26 Earnings Review
Twilio's Q3 revenue rose 20% to $1.56 billion, but Q4 organic growth guidance fell to 11% to 12% and RPO declined 28%.
Twilio's Q3 revenue rose 20% to $1.56 billion, but Q4 organic growth guidance fell to 11% to 12% and RPO declined 28%.
$toi https://t.co/9pfaLXskXk
@thecontracap also worth noting that if $ANAB loses, maybe the stock goes down but future cash flows do not. Plan B is prob just sell the royalty stream, which is why the former CFO of $RPRX was added to the BOD 4 months ago. Heads win a ton. Tails you don't lose (if you can handle the vol)
@thecontracap agree ex-CEO statements are not +. However, statements from the GSK manager responsible for managing the $ANAB collaboration make it clear he thought GSK was in violation of the agreement. Not good for either side. Think sanctity of contract law has to come above all else though
@thecontracap 2/x)on the other hand, if $ANAB's position is upheld, it sucks for GSK, but contract law as a whole in DE continues to successfully govern the land as it has for centuries prior. Not clear to me that AI can consider the gravity of dismantling all of DE contract law...
@thecontracap 1/x)$ANAB also not a lawyer but seems to me that the implications of GSK's position would be catastrophic for contract law in DE if supported by the court. Effectively, any acquiror could disavow the obligations of a purchased subsidiary. Which seems "absurd" in the legal sense.
Marvell and Lumentum’s merger targets uVCSEL scale-in optics, combining Marvell’s DSP and analog IP with Lumentum’s laser manufacturing for…
Stevanato fell 30% after forecasting low-single-digit 2027 growth as lower Nexa syringe volumes from a GLP-1 customer offset solid Q3…
Transocean enters its Valaris merger with 109 of 110 available deepwater rigs contracted and 313 million shares sold short, despite weaker…
BXDC trades at a 14% discount to net liquidation value, with $1.9 billion of cash against a $1.6 billion market cap, ahead of data-center…
Veeva Systems' Commercial Solutions returned to 13% subscription growth, while R&D and Quality grew 19.3%, with Falcon AI agents and…
Marvell’s proposed Lumentum deal risks alienating Cloudlight customers and losing engineering talent, despite limited optical integration…
ARS Pharmaceuticals’ neffy adoption and insurance hurdles have driven cash burn and a falling share price, while management targets…
Marvell Technology and Lumentum fell sharply after announcing a historic merger, reviving comparisons with JDS-Uniphase.
FTAI Aviation’s $234 million Jereh JV deposit funds Power inventory, while customer concentration, lower cash guidance and pending U.S.
Grab’s Southeast Asian delivery business nears a profitability inflection point, while consolidation and a potential GoTo deal challenge…
BioMarin's Q3 revenue rose 32% to $1.02 billion after the Amicus acquisition, while Alesta charges drove an $82 million operating loss and…
BioNTech's Q3 revenue beat consensus on €613 million of BMS partnership revenue, while COVID vaccine sales fell 35% and net cash totaled…
Onsemi's Q3 revenue rose 11% to $1.72 billion, driven by 175% AI data-center growth, while automotive revenue fell 1% and net debt dropped…
Marvell’s all-stock Lumentum deal exposes LITE holders to MRVL volatility while paying peak-cycle AI multiples, with US and China antitrust…
BSP · short Bending Spoons is a software and digital-assets holding company that has completed more than 50 acquisitions since 2013.
Nebius faces refinancing and dilution risks from short-term borrowing and heavy GPU infrastructure spending despite higher rental prices…
DoorDash’s 3Q orders rose 28% as it announced a $17 billion Instacart acquisition, expanding its grocery basket strategy after buying…
Reddit’s Google referrals fell by more than 1 million a week as AI search expands, prompting a logged-in-user push to protect ad yield and…
Iron Mountain’s upgraded Q2 guidance, revenue, EBITDA and AFFO trends support its outlook before Nov.
Global Payments rose 18% on a reported CD&R and GTCR take-private bid, while estimated control value is $45-$60 versus a $96.84 share price.
Every publication on this site, hand-picked.
Every account on this site, hand-picked.
Ordered by how often our editor reaches for them.